bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to...Show More

bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to update its Compliance Plan by September 4, 2024, and intends to file the necessary reports as soon as possible. Despite the notices, there is no immediate impact on the trading of bluebird bio's securities on Nasdaq. The company has issued a press release on August 23, 2024, to publicly announce the receipt of the Nasdaq notices.